Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation

Financialisation and small firms: A qualitative analysis of bioscience and film and media firms

“…business sector is dwarfed by what all our firms referred to as 'big pharma', most notably GSK (GlaxoSmithKline), Pfizer and Astra-Zeneca. Resonating with other research on the vertical disintegration of big pharma (seeGleadle, Parris and Shipman, 2014), our interviewees noted that the high costs of R&D coupled with the uncertainty of market returns mean that bioscience innovation has, in essence, been out-sourced to small firms like Bio1, 2 and 4. For such small firms, failure rates are notoriously high:…”

The Variegated Financialization of Housing

“…The increasing financialization of non‐financial firms has been noted across a wide range of industries, for example the car industry (Froud et al ., ; ), the so‐called ‘new economy’ (Feng et al ., ), retail (Baud and Durand, ), computing (Froud et al ., ), pharmaceuticals (Gleade et al ., ), insurance (Wissoker, ), aviation (Muellerleile, ), infrastructure (Torrance, ; Allen and Pryke, ; O'Neill, ; Ashton et al ., ) and real estate (Smart and Lee, ; Guironnet et al ., ; Wijburg and Aalbers, ). Many of the articles in this symposium provide further evidence for the financialization of traditionally non‐financial firms.…”

Aquisição de pequenas empresas: um estudo sobre o setor biofarmacêutico

“…Uma vasta literatura defende que as grandes empresas farmacêuticas escolheram as aquisições de pequenas empresas como forma de incorporar novas tecnologias (Comanor e Scherer, 2013;Gleadle et al, 2013;Light e Lexchin, 2012;Hopkins et al, 2012;Higgins e Rodriguez, 2006;Matos, 2016;Munos 2009;Paul et al, 2009). Matos (2016) reforça que há uma divisão dentro do próprio processo inovativo, no qual as pequenas empresas cada vez mais se atêm as etapas iniciais de descoberta de novas moléculas, enquanto as grandes empresas estão focadas na condução dos testes clínicos.…”